ISRCTN ISRCTN85256968
DOI https://doi.org/10.1186/ISRCTN85256968
Sponsor Ambrosiana Nursing Home in Cesano Boscone, Piazza Monsignor Moneta
Funder Ambrosiana Nursing
Submission date
01/10/2026
Registration date
02/10/2026
Last edited
06/10/2026
Recruitment status
No longer recruiting
Overall study status
Completed
Condition category
Musculoskeletal Diseases
Prospectively registered
Protocol
Statistical analysis plan
Results
Individual participant data
Record updated in last year

Plain English summary of protocol

Not provided at time of registration

Contact information

Dr Maria Elena Malighetti
Principal investigator, Scientific, Public

Piazza Monsignor Moneta, 1 - 20090 Cesano Boscone (MI)
Milano
20122
Italy

Phone +39 (0)3474243484
Email mariaelena.malighetti@gmail.com

Study information

Primary study designObservational
Observational study designCross sectional study
Scientific titlePrevalence and predictors of sarcopenia in elderly adults with type 2 diabetes: an Italian cross-sectional study
Study acronymSARCODIAB
Study objectives The study conducted at the community diabetes clinic in Cesano Boscone (Milan) aimed to assess the prevalence of sarcopenia in patients with type 2 diabetes mellitus (T2DM) followed at the clinic.
Ethics approval(s)

Approved 23/06/2026, Territorial Ethics Committee Lombardy 3 (via Francesco Sforza 28, Milano, 20122, Italy; +39 (0)255032982; cetlombardia3@policlinico.mi.it), ref: ID 7296 – parere numero 7296_10.06.2026_P_bis

Health condition(s) or problem(s) studiedSarcopenia in diabetic patients
MethodologyAn observational, cross-sectional, retrospective study. Patient data will be extracted from the diabetes medical records held at the center:

Initial functional assessment through two fundamental tests:
1. Handgrip test (manual grip strength): pathological if <32 kg in men and <19 kg in women
2. Chair Stand Test (CST): considered positive if the time required for five lifts from the chair - without aid - exceeds 12 seconds

Instrumental examination:
Only if both tests are positive, a muscle ultrasound of the quadriceps femoris is carried out to objectify the thickness of the muscle itself

BMI indexing:
1. The value of muscle thickness (in cm) is divided by the patient's BMI to obtain the muscle/BMI index
2. Diagnostic cut-offs:
2.1. <1.4 in men
2.2. <1.0 in women

Parameters and tests used:
For patients included in the study, the following parameters were analyzed:
1. T0 blood tests: HbA1c, creatinine
2. Anthropometric evaluations: weight, height, BMI, waist circumference
3. Hypoglycemic therapy in progress

Muscle functional tests:
1. Handgrip Test: evaluation of grip strength (kg)
2. Chair Standing Test (CST): measure of the time needed to perform five lifts from the chair with arms crossed
3. Muscle ultrasound of the quadriceps femoris (carried out if both of the above tests were positive)
Intervention typeOther
Primary outcome measure(s)
  1. The prevalence of sarcopenia in patients with type 2 diabetes mellitus, measured using patient data extracted from the diabetes medical records held at the center, measured at a single timepoint
Key secondary outcome measure(s)
Completion date22/10/2025

Eligibility

Participant type(s)
Age groupMixed
Lower age limit60 Years
Upper age limit90 Years
SexAll
Target sample size at registration1000
Total final enrolment1000
Key inclusion criteriaDocumented diagnosis of type 2 diabetes in patients aged ≥65 years, or aged <65 years with at least one comorbidity associated with an increased risk of sarcopenia, including: CKD, RD, PAD, CVD, PN, obesity, chronic physical inactivity, metabolic liver disease, heart failure, depression, transplantation, steroid therapy, significant weight loss, osteoarthritis, cognitive decline, neurological diseases, history of cerebrovascular events, recent hospitalization, recurrent falls, chronic tiredness, fatigue, and progressive movement limitations.
Key exclusion criteria1. Unstable clinical status (acute infections, acute heart or renal failure) or neoplasms
2. Objective inability to perform the required functional tests
Date of first enrolment01/01/2025
Date of final enrolment30/06/2025

Locations

Countries of recruitment

  • Italy

Study participating centres

Results and Publications

Individual participant data (IPD) Intention to shareNo

Study outputs

Output type Details Date created Date added Peer reviewed? Patient-facing?
Protocol file 02/10/2026 No No

Additional files

50383_Protocol.pdf
Protocol file

Editorial Notes

06/10/2026: The contact and funder details were corrected.
05/10/2026: Internal review.
02/10/2026: Study's existence confirmed by the Territorial Ethics Committee Lombardy 3.